Skip to main content
VRDN logo

VRDN · Viridian Therapeutics, Inc.\DE

$19.18 +0.62 (+3.34%) At close · Jul 21
Market Cap
$1.98B
Shares
103.07M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Stephen Mahoney $6,776,249
Radhika Tripuraneni $4,080,466
Thomas Beetham $3,761,182
Seth Harmon $2,642,779
Jennifer Tousignant $2,351,915
Fiscal 2024
Executive Total
Jennifer Tousignant $4,911,024
Dr. Barrett Katz $2,160,823
Dr. Thomas Ciulla $1,610,609
Stephen Mahoney $1,117,454
Thomas Beetham $809,500
Seth Harmon $770,659
Fiscal 2023
Executive Total
Scott D. Myers $36,407,990
Stephen Mahoney $12,479,521
Dr. Thomas Ciulla $10,646,112
Seth Harmon $6,548,526
Thomas Beetham $4,761,402
Dr. Barrett Katz $3,275,999
Jonathan Violin $2,211,072
Jennifer Tousignant
Fiscal 2022
Executive Total
Jonathan Violin $4,646,740
Barrett Katz $2,110,655
Dr. Barrett Katz $2,110,655
Kristian Humer $2,023,780
Seth Harmon
Thomas Beetham
Stephen Mahoney
Jennifer Tousignant
Dr. Thomas Ciulla
Fiscal 2021
Executive Total
Jonathan Violin $17,408,538
Barrett Katz $8,167,089
Kristian Humer $7,708,958
Lee Rauch $1,779,054
Jennifer Tousignant
Dr. Thomas Ciulla
Thomas Beetham
Fiscal 2020
Executive Total
William S. Marshall $2,186,819
Lee Rauch $1,670,411
Diana Escolar $865,618
Jason Leverone $483,020
Fiscal 2019
Executive Total
William S. Marshall $1,075,942
Paul D. Rubin $632,738
Diana Escolar $550,005
Jason Leverone $537,807
Fiscal 2018
Executive Total
William S. Marshall $1,987,005
Paul D. Rubin $976,769
Jason Leverone $824,667
Key facts CIK 1590750 CUSIP 92790C104 13F (30d) 14 filings 14 filers Visit website Investor relations